Profile data is unavailable for this security.
About the company
Lincoln Pharmaceuticals Limited is engaged in the business of manufacturing and trading of pharmaceuticals products like medicines, injections and other related products. The Company’s product categories include tablets, capsules, liquid injection, cream in tubes, eye/ear drops, dry power injection, liquid in bott, liquid injection and pharma products. It has operations in cardiac, diabetic, anti-malarial, anti-biotics, cephalosporins, analgesic, antipyretics, vitamin-minerals and iron preparations, among others. The Company serves approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia and 26 States across India. The Company's products include ARHL Tablet (used to treat chloroquine resistant falciparum malaria symptoms), Ibuprofen Tablet (used to treat pain, fever, and inflammation), Dolomol Tablet (used to treat aches and pains), Namcold Tablet (used to treat common cold symptoms) and Tinnex Capsule used to treat tinnitus.
- Revenue in INR (TTM)5.81bn
- Net income in INR933.05m
- Incorporated1995
- Employees1.70k
- LocationLincoln Pharmaceuticals LtdLINCOLN HOUSE, B/h. Satyam ComplexScience City Road, SolaAHMEDABAD 380060IndiaIND
- Phone+91 7 967778000
- Fax+91 7 930018062
- Websitehttps://www.lincolnpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bajaj Healthcare Ltd | 4.73bn | -143.27m | 8.57bn | 1.06k | -- | 3.08 | 64.51 | 1.81 | -5.18 | -30.36 | 171.62 | 100.86 | 0.5681 | 1.44 | 2.32 | -- | -1.72 | 6.97 | -3.51 | 12.73 | 46.18 | 30.16 | -3.03 | 7.20 | 0.8096 | 1.64 | 0.5446 | 5.38 | -29.69 | 5.04 | -133.30 | -- | 15.08 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.09bn | 224.63m | 9.04bn | 940.00 | 40.35 | 4.82 | 37.45 | 4.33 | 8.47 | 8.47 | 78.31 | 70.88 | 1.01 | 5.27 | 13.12 | -- | 10.90 | 10.95 | 12.30 | 13.29 | 55.00 | 58.17 | 10.76 | 9.21 | 9.63 | 26.29 | 0.0455 | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| Bliss GVS Pharma Ltd | 7.70bn | 754.54m | 11.04bn | 763.00 | 14.88 | 1.14 | 10.22 | 1.43 | 7.08 | 7.08 | 72.86 | 92.39 | 0.6498 | 3.45 | 1.95 | -- | 6.88 | 6.46 | 8.37 | 8.22 | 50.39 | 44.21 | 10.59 | 9.92 | 4.34 | 17.97 | 0.0905 | 7.93 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Vimta Labs Ltd | 3.18bn | 410.09m | 11.09bn | 1.37k | 27.43 | 3.47 | 14.75 | 3.49 | 18.24 | 18.24 | 141.64 | 144.20 | 0.8349 | 3.23 | 3.81 | -- | 10.76 | 10.53 | 12.60 | 12.77 | 76.02 | 73.65 | 12.89 | 12.16 | 2.46 | 24.79 | 0.0566 | 11.15 | 0.0223 | 8.40 | -14.87 | 10.13 | 35.88 | 0.00 |
| Syncom Formulations (India) Ltd | 2.63bn | 253.14m | 11.94bn | 799.00 | 37.35 | 4.14 | 39.74 | 4.53 | 0.34 | 0.34 | 3.56 | 3.07 | 0.6732 | 7.42 | 2.95 | -- | 6.47 | 7.50 | 9.00 | 10.23 | 40.44 | 34.59 | 9.61 | 9.38 | 2.38 | 5.57 | 0.201 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Beta Drugs Ltd | 2.56bn | 347.57m | 12.02bn | 315.00 | 34.59 | 8.47 | 26.26 | 4.70 | 36.15 | 36.15 | 266.28 | 147.68 | 1.24 | 4.44 | 3.72 | 8,126,721.00 | 16.85 | -- | 25.36 | -- | 41.88 | -- | 13.58 | -- | 1.43 | 18.21 | 0.098 | -- | 23.54 | -- | 23.73 | -- | -- | -- |
| Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 12.23bn | 38.00 | 129.85 | 47.06 | 136.14 | 27.15 | 15.98 | 15.98 | 90.25 | 44.09 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
| Lincoln Pharmaceuticals Ltd | 5.81bn | 933.05m | 12.43bn | 1.70k | 13.32 | 2.10 | 11.96 | 2.14 | 46.58 | 46.58 | 289.81 | 295.98 | 0.9017 | 3.78 | 3.90 | -- | 14.49 | 13.95 | 16.61 | 16.54 | 52.06 | 51.21 | 16.07 | 14.71 | 4.01 | 60.95 | 0.0018 | -- | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Kopran Ltd | 6.15bn | 509.56m | 12.53bn | 394.00 | 24.74 | 2.55 | 19.62 | 2.04 | 10.50 | 10.50 | 126.95 | 101.90 | 0.8824 | 2.99 | 3.28 | -- | 7.32 | 8.47 | 10.22 | 12.23 | 34.60 | 34.18 | 8.29 | 8.89 | 1.44 | 43.23 | 0.168 | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| Ngl Fine Chem Ltd | 3.39bn | 413.43m | 14.44bn | 343.00 | 34.93 | 5.50 | 27.27 | 4.26 | 66.92 | 66.92 | 548.61 | 425.11 | 1.05 | 4.51 | 4.36 | -- | 12.87 | 15.06 | 16.61 | 19.58 | 53.18 | 46.79 | 12.20 | 13.15 | 1.96 | 30.64 | 0.1218 | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
| Zota Health Care Ltd | 1.80bn | -143.48m | 15.03bn | 338.00 | -- | 16.28 | 261.71 | 8.33 | -5.59 | -5.59 | 70.40 | 34.81 | 0.9341 | 2.02 | 6.55 | -- | -7.42 | -1.38 | -10.54 | -1.85 | 46.43 | 36.48 | -7.95 | -1.33 | 0.7851 | -2.62 | 0.5143 | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Windlas Biotech Ltd | 6.31bn | 581.87m | 15.07bn | 1.05k | 25.81 | 3.33 | 21.04 | 2.39 | 27.94 | 27.94 | 302.99 | 216.33 | 1.09 | 5.79 | 4.99 | -- | 10.07 | -- | 13.50 | -- | 37.21 | -- | 9.22 | -- | 2.15 | 58.58 | 0.008 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| Hester Biosciences Ltd | 3.05bn | 188.89m | 16.09bn | 693.00 | 75.98 | 5.51 | 41.96 | 5.28 | 24.89 | 24.89 | 392.38 | 343.01 | 0.4572 | 1.20 | 3.85 | -- | 3.18 | 6.15 | 4.00 | 7.69 | 68.52 | 68.83 | 6.95 | 12.83 | 1.31 | 1.84 | 0.4466 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
Data as of Jun 14 2024. Currency figures normalised to Lincoln Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
0.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| American Century Investment Management, Inc.as of 09 May 2024 | 14.10k | 0.07% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 13.26k | 0.07% |
| Fidelity Management & Research Co. LLCas of 30 Apr 2024 | 5.46k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 30 Apr 2024 | 1.43k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 30 Apr 2024 | 136.00 | 0.00% |
| Carne Global Fund Managers (Ireland) Ltd.as of 30 Sep 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.
